Boston Scientific stock came under fresh pressure this month after two Wall Street firms slashed their price targets even as both kept Buy ratings in place. Bank of America cut its target on Boston Scientific Corporation to $68 from $105 on May 18, while Argus earlier trimmed its target to $95 from $115 on April 27.
That kind of move matters because it changes the math on a company many investors have treated as a steadier name in medical devices. Boston Scientific manufactures, develops and markets devices used in interventional medical procedures, with operations split between Cardiovascular and MedSurg. Cardiovascular covers Cardiology and Peripheral Interventions, while MedSurg includes Urology, Endoscopy and Neuromodulation.
Bank of America said it had hosted 34 medtech companies last week in Las Vegas and updated several price targets to reflect what it called the new reality of medtech valuations. In its view, the sector is facing a year of few product cycles, inflation kicking up post-war, ACA-related pressure, utilization worries and a broader shift in investor attention toward data centers over healthcare. Even so, the firm reaffirmed a Buy rating on Boston Scientific shares.
Argus also stayed constructive, keeping a Buy rating after the company’s fiscal first-quarter earnings and guidance cut. The firm said Boston Scientific stock has recently underperformed the broader market, but argued the company remains well-positioned in cardiovascular, electrophysiology and neuromodulation. Argus added that management set more achievable objectives by cutting its outlook, a move that can reduce the risk of another disappointment if the business tracks to plan.
The two research notes point in the same direction, even if they land at different valuations: analysts still see Boston Scientific as a quality medtech franchise, but one that now has to be priced against a slower, more skeptical market. That is a notable shift for a stock that had been described as one of the best medical stocks to invest in according to billionaires, and it leaves the company with a lower bar to clear when it reports next.
For investors watching bsx stock, the immediate question is no longer whether analysts like the business. They do. The question is whether Boston Scientific can deliver enough growth in its core cardiovascular and neuromodulation areas to justify the latest reset in expectations, or whether valuation pressure across medtech keeps pulling the shares toward the lower targets now on the table.
